COMMUNIQUÉS West-GlobeNewswire

Children’s National ranked among top children’s hospitals nationwide and highest in the DMV by U.S. News & World Report
15/09/2026
Ranked in all 11 specialties, with top 10 honors in neurology and neurosurgery, cancer, orthopedics, gastroenterology and GI surgery, neonatology, and diabetes and endocrinology Washington, DC, Sept. 15, 2026 (GLOBE [...]
CORRECTED — Impact Biomedical Inc (NYSE: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Limited (f/k/a Dr Ashleys Limited)
15/09/2026
HOUSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) -- This corrected press release is being issued to correct the merger exchange ratio that was incorrectly stated in the press release of Impact Biomedical Inc. (the “ Company ” [...]
DLH Appoints Brooke Pierce President of Health Business Group
14/09/2026
ATLANTA, Sept. 14, 2026 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of digital, engineering, and scientific solutions for health and defense missions, today [...]
Curium™ announces FDA approval of BEXLUTRY lutetium Lu 177 dotatate injection for adults with SSTR-positive GEP-NETs
14/09/2026
BEXLUTRY is the first radioligand equivalent for the treatment of GEP-NETs in adults and the first radioligand therapy from Curium™ approved by the FDA BOSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Curium™ announced today [...]
Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases
15/09/2026
- All rights to TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon Semaglutide, will revert to Ascendis - Ascendis to initiate multiple programs in metabolic and [...]
Ascendis Announces Planned $400 Million Share Repurchase Program
15/09/2026
COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its Board of Directors has authorized the Company to repurchase up to $400 million of the Company’s [...]
From Former Patient to Clinical Leader: Oxford Treatment Center Promotes Kate Bell to Outpatient Clinical Manager
15/09/2026
OXFORD, Miss., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Oxford Treatment Center is pleased to announce the promotion of Kate Bell, NCC, LPC , to Outpatient Clinical Manager. Bell first came to Oxford Treatment Center as a [...]
Health Catalyst Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
15/09/2026
SALT LAKE CITY, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst” or the “Company,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health [...]
Neutra Corp's Neutra Life Sciences Expands 2026 Industry Conference Schedule to Deepen Sponsor and CRO Relationships Across Its Site Network
14/09/2026
HOUSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Neutra Corp (OTC: NTRR), a company focused on health, wellness, and life sciences, today announced that its wholly owned clinical research Site Management Organization (SMO) [...]
Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update
14/09/2026
All six Cohort 1 (low dose BB-301) patients have completed the full 12-month post-treatment follow-up period, and Cohort 2 (high dose BB-301) is fully enrolled with all three patients having been safely treated A Type C [...]
BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long Covid
14/09/2026
Conference call scheduled for Tuesday, September 15, 2026, at 8:30 a.m. Eastern Time (ET) CARSON CITY, Nev., Sept. 14, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or the "Company"), a clinical-stage [...]
Biodesix Quality and Regulatory Executive, Brianna Phillips, to speak at upcoming RAPS and SOCRA Annual Meetings
14/09/2026
Industry-leading QA/RA excellence accelerates patient access to Biodesix Lab testing, which helps improve overall outcomes for patients with lung nodules LOUISVILLE, Colo., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Biodesix, [...]
Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results
14/09/2026
KIRKLAND, Wash., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today reported financial results for the first [...]
Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial
14/09/2026
Post hoc analyses of SION-719 PreciSION CF subset showed a mean placebo-adjusted sweat chloride reduction of up to -8.6 mmol/L consistent with NBD1 biological activity Dual combination Phase 2a trial expected to [...]
NurExone and NanoPass Technologies Ltd. to Collaborate on Integrated Exosome Delivery Approach for Regenerative Eye and Skin Applications
14/09/2026
Collaboration to evaluate MicronJet™ with NurExone exosomes across ophthalmic and aesthetic applications in multi-billion-dollar markets TORONTO and HAIFA, Israel, Sept. 14, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic [...]
Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study
14/09/2026
-- Topline Phase 1 data shows generally favorable safety and tolerability profile of AGMB-447 -- -- Pharmacokinetic profile confirms efficient lung restriction with low systemic exposure and high exposure of AGMB-447 in [...]
Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer
14/09/2026
Company receives third Breakthrough Therapy Designation for RASONQUE and fifth across its portfolio of RAS(ON) inhibitors, further highlighting its differentiated strategy for developing innovative medicines for [...]
PetMeds Appoints Andrew Parry as Chief Technology Officer
14/09/2026
DELRAY BEACH, Fla., Sept. 14, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx (Nasdaq: PETS), today announced the appointment of Andrew Parry as Chief Technology Officer, [...]
PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors
14/09/2026
Gross Proceeds of $11.3 Million at Initial Closing Transaction Led by Dr. Patrick Soon-Shiong, Founder of NantWorks PRINCETON, N.J., Sept. 14, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS [...]

Pages